Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402))

Research output: Contribution to journal › Comment/debate

Access to Document

@article{7dc0c6c96d8a4599836234517cf92895,

title = "Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402))",

author = "G. Cheng and Saleh, \{M. N.\} and C. Marcher",

year = "2011",

doi = "10.1016/S0140-6736(11)60140-2",

language = "English (UK)",

volume = "377",

pages = "640",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "9766",

}

TY - JOUR

T1 - Eltrombopag for management of chronic immune thrombocytopenia (RAISE)

T2 - A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402))

AU - Cheng, G.

AU - Saleh, M. N.

AU - Marcher, C.

PY - 2011

Y1 - 2011

UR - https://www.scopus.com/pages/publications/79951812873

U2 - 10.1016/S0140-6736(11)60140-2

DO - 10.1016/S0140-6736(11)60140-2

M3 - Comment/debate

AN - SCOPUS:79951812873

SN - 0140-6736

VL - 377

SP - 640

JO - The Lancet

JF - The Lancet

IS - 9766

ER -